OMER Stock Analysis: Omeros | NASDAQ

Complement Inhibitors, Immunologic Therapeutics, Oncology, Addiction Treatments

Total Rating 68

Safety 32

Buy Signal 1.80

Biotechnology
Industry Rotation: +8.4

Market Cap: 1.35B
Avg Turnover: 28.5M

Risk 3d forecast

Volatility110%

VaR 5^th Pctl14.2%

VaR vs Median-14.4%

Reward TTM

Sharpe Ratio1.37

Rel. Str. IBD98.8

Rel. Str. Peer Group93.5

Character TTM

Beta0.674

Beta Downside-0.674

Hurst Exponent0.412

Drawdowns 3y

Max DD75.56%

CAGR/Max DD1.03

CAGR/Mean DD2.41

EPS (Earnings per Share)

Last SUE: 0.85
Qual. Beats: 2

Revenue

Last SUE: 4.00
Qual. Beats: 2

Warnings

Earnings Expected To Drop (P/E To P/E Forward)

Strong Share Dilution

Beneish M-Score Likely Earnings Manipulation

Altman Z'' In Financial Distress Zone

Tailwinds

Supp Ema8

Rs Leader

Idiosyncratic Leader

Tailwind

Confidence

Seasonality 11.6 years of data

Jan -3.7% 19

Feb +1.7% 31

Mar +8.7% 16

Apr +2.0% 26

May -5.5% 41

Jun +0.2% 7

Jul +14.3% 34

Aug -0.8% 13

Sep -8.4% 33

Oct -12.0% 25

Nov +23.0% 30

Dec -5.7% 12

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: OMER Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, founded in 1994 and listed on NASDAQ. The company focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for orphan indications, particularly within immunologic diseases. As a clinical-stage company with no approved products on the market, Omeros relies on external financing and capital markets to fund its research and development activities.

The companys lead product candidate is narsoplimab (OMS721), a MASP-2 inhibitor being developed for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA) and currently in Phase II trials for COVID-19-related acute respiratory distress syndrome. Its pipeline also includes OMS1029, which has completed Phase I trials targeting lectin pathway disorders, and OMS527, which is in Phase I trials for addictions, compulsive disorders, movement disorders, and cocaine use disorder.

Omeros is additionally advancing several preclinical programs, including MASP-2-directed therapeutics for lectin pathway disorders, MASP-3 small-molecule inhibitors for alternative pathway disorders, OncotoX-AML for acute myeloid leukemia, and a Targeted Complement Activating Therapy aimed at multidrug-resistant organisms. The companys focus on orphan indications positions its candidates to benefit from regulatory pathways that provide extended market exclusivity, fee waivers, and tax credits for therapies targeting rare diseases.

Headlines to Watch Out For

Narsoplimab FDA approval and commercial launch in TA-TMA indication
Phase III narsoplimab IgA nephropathy trial data readout
Cash burn raises dilutive financing risk amid pipeline development

Piotroski VR-10 (Strict) 4.0

Net Income: 124.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.44 > 0.02 and ΔFCF/TA 101.7 > 1.0
NWC/Revenue: 235.0% < 20% (prev -3.85k%; Δ 4.08k% < -1%)
CFO/TA -0.24 > 3% & CFO -68.7m > Net Income 124.8m
Net Debt (226.0m) to EBITDA (136.2m): 1.66 < 3
Current Ratio: 1.95 > 1.5 & < 3
Outstanding Shares: last quarter (89.6m) vs 12m ago 52.98% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 15.77% > 50% (prev 0.21%; Δ 15.56% > 0%)
Interest Coverage Ratio: 3.72 > 6 (EBIT TTM 132.1m / Interest Expense TTM 35.6m)

Altman Z'' -4.05

A: 0.31 (Total Current Assets 185.2m - Total Current Liabilities 95.0m) / Total Assets 286.8m
B: -2.94 (Retained Earnings -844.4m / Total Assets 286.8m)
C: 0.54 (EBIT TTM 132.1m / Avg Total Assets 243.7m)
D: -0.15 (Book Value of Equity -51.3m / Total Liabilities 338.2m)
Altman-Z'' = -4.05 = D

Beneish M 1.00

DSRI: 0.10 (Receivables 21.3m/34.5m, Revenue 38.4m/412k)
GMI: 1.00 (fallback, negative margins)
AQI: 0.56 (AQ_t 0.32 / AQ_t-1 0.58)
SGI: 93.26 (Revenue 38.4m / 412k)
TATA: 0.67 (NI 124.8m - CFO -68.7m) / TA 286.8m)
Beneish M = 62.19 (Cap -4..+1) = D

What is the price of OMER shares?

As of August 28, 2026, the stock is trading at USD 19.25 with a total of 1,756,257 shares traded. Over the past week, the price has changed by +3.33%, over one month by +69.75%, over three months by +73.89% and over the past year by +352.94%.

Current recommended Stop Loss: 17.00 (which is 11.7% or 2.4 ATR below the current price).

Is OMER a buy, sell or hold?

Omeros has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy OMER.

StrongBuy: 2
Buy: 0
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the OMER price?

Analysts Target Price	33	71.4%

Omeros (OMER) - Fundamental Data Overview as of 22 August 2026

Market Cap USD = 1.35b (1.35b USD * 1.0 USD.USD)
P/E Trailing = 11.1557
P/E Forward = 36.7647
P/S = 35.0995
P/B = 8.4414
P/EG = 0.8053
Revenue TTM = 38.4m USD
EBIT TTM = 132.1m USD
EBITDA TTM = 136.2m USD
Long Term Debt = 208.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 37.8m USD (from shortTermDebt, last quarter)
Debt = 258.4m USD (corrected: LT Debt 208.5m + ST Debt 37.8m) + Leases 12.0m
Net Debt = 226.0m USD (calculated: Debt 258.4m - CCE 32.4m)
Enterprise Value = 1.57b USD (1.35b + Debt 258.4m - CCE 32.4m)
Interest Coverage Ratio = 3.72 (Ebit TTM 132.1m / Interest Expense TTM 35.6m)
EV/FCF = 12.51x (Enterprise Value 1.57b / FCF TTM 125.8m)
FCF Yield = 7.99% (FCF TTM 125.8m / Enterprise Value 1.57b)
FCF Margin = 327.5% (FCF TTM 125.8m / Revenue TTM 38.4m)
Net Margin = 324.9% (Net Income TTM 124.8m / Revenue TTM 38.4m)
Gross Margin = unknown ((Revenue TTM 38.4m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 5.49 (Enterprise Value 1.57b / Total Assets 286.8m)
Interest Expense / Debt = 13.76% (Interest Expense 35.6m / Debt 258.4m)
Taxrate = 0.44% (29.0k / 6.67m)
NOPAT = 131.5m (EBIT 132.1m * (1 - 0.44%))
Current Ratio = 1.83 (Total Current Assets 185.2m / Total Current Liabilities 101.3m)
Debt / Equity = -5.03 (negative equity) (Debt 258.4m / totalStockholderEquity, last quarter -51.3m)
Debt / EBITDA = 1.66 (Net Debt 226.0m / EBITDA 136.2m)
Debt / FCF = 1.80 (Net Debt 226.0m / FCF TTM 125.8m)
Total Stockholder Equity = -114.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 51.22% (Net Income 124.8m / Total Assets 286.8m)
RoE = -109.4% (negative equity) (Net Income TTM 124.8m / Total Stockholder Equity -114.1m)
RoCE = 139.9% (EBIT 132.1m / Capital Employed (Equity -114.1m + L.T.Debt 208.5m))
RoIC = 57.74% (NOPAT 131.5m / Invested Capital 227.8m)
WACC = 9.21% (E(1.35b)/V(1.61b) * Re(8.35%) + D(258.4m)/V(1.61b) * Rd(13.76%) * (1-Tc(0.00)))
Discount Rate = 8.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.74 | Cagr: 20.60%
[DCF] Terminal Value 72.47% ; FCFF base≈125.8m ; Y1≈126.3m ; Y5≈133.8m
[DCF] Fair Price = 21.96 (EV 1.82b - Net Debt 226.0m = Equity 1.59b / Shares 72.4m; r=9.21% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.85 | # QB: 2
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-0.03 | Chg30d=+90.74% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.66 | Chg30d=+73.68% | Revisions=+0% | GrowthEPS=-68.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=1.15 | Chg30d=+838.71% | Revisions=-25% | GrowthEPS=+73.5% | GrowthRev=+57.5%
[Analyst] Revisions Ratio: +0% (up=1, down=1)